Bishoy A Gayed, Jessica Gillen and Alana Christie contributed equally to this work.
No authors have any direct or indirect commercial financial incentive associated with publishing the article. The present manuscript or portions thereof are not under consideration by another journal or electronic publication and have not been previously published. All authors declare that they have no competing interests.
BG conception/design; analysis/interpretation; writing. JG conception/design; analysis/interpretation; writing. AC analysis/interpretation; writing. SPL - conception/design; analysis/interpretation; writing. XJX - conception/design; analysis/interpretation; writing. JY - conception/design; analysis/interpretation; writing. JK - conception/design; analysis/interpretation; writing. GR - analysis/interpretation; writing. AS - analysis/interpretation; writing. YL - analysis/interpretation; writing. VM - design, analysis/interpretation; writing. JB - conception/design; analysis/interpretation; writing and funding. All authors read and approved the final manuscript.
To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC).
We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables.
Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses.
Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.
Campbell SC, Lane, BR. Malignant Renal Tumors. In: Campbell-Walsh Urology, 10th Edition. 10th edn. Edited by Kavoussi L, Novick A, Partin A, Peters C; 2012: 1443–1444.
Vaishampayan U, Vankayala H, Vigneau FD, Quarshie W, Dickow B, Chalasani S, et al. The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Canc. 2014;12(2):124–9. CrossRef
Haas NB, Uzzo RG. Targeted therapies for kidney cancer in urologic practice. Urol Oncol-Semin Ori. 2007;25(5):420–32. CrossRef
Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999;19(4A):2583–90. PubMed
Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, et al. The effects of angiopoietin-1 and −2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 2001;61(4):1255–9. PubMed
Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(9):1498–505. PubMed
Bhaskar A, Gupta R, Vishnubhatla S, Kumar L, Sharma A, Sharma MC, et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Luek Lymphoma. 2013;54(7):1473–8. CrossRef
Bullock AJ, Zhang L, O’Neill AM, Percy A, Sukhatme V, Mier JW, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). [Abstract] J Clin Oncol. 2010;28:15s. suppl; abstr 4630.
Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, et al. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res. 2010;30(2):375–81. PubMed
Singer EA, Gupta GN, Marchalik D, Srinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 2013;25(3):273–80. PubMed
- Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma
Bishoy A Gayed
Jose A Karam
Arthur I Sagalowsky
- BioMed Central
Neu im Fachgebiet Urologie
Meistgelesene Bücher in der Urologie
Mail Icon II